Related Experiment Video
Updated: Feb 15, 2026

Using the Chicken Chorioallantoic Membrane In Vivo Model to Study Gynecological and Urological Cancers
Published on: January 28, 2020
[Clinical study on cefmenoxime (CMX) in urology]
Cefmenoxime (CMX) demonstrates effective serum concentrations and a favorable half-life across different administration routes. This new cephalosporin antibiotic shows high efficacy in treating urinary tract infections, including resistant strains.
Area of Science:
- Pharmacology
- Microbiology
- Clinical Medicine
Context:
- Cefmenoxime (CMX) is a novel cephalosporin antibiotic.
- Urinary tract infections (UTIs) represent a significant clinical challenge.
- Assessing the pharmacokinetic and therapeutic profile of new antibiotics is crucial.
Purpose:
- To evaluate the serum pharmacokinetics of Cefmenoxime (CMX) following intramuscular and intravenous administration.
- To determine the efficacy of CMX in treating various types of urinary tract infections.
- To assess the safety and tolerability profile of CMX.
Summary:
- Pharmacokinetic studies in healthy adults showed CMX achieved peak serum concentrations ranging from 5.9 to 12.4 µg/ml with half-lives between 0.94 and 1.41 hours.
- Urinary recovery of CMX ranged from 60-70% within 6 hours.
- CMX demonstrated 100% efficacy in acute simple cystitis and 70% efficacy in complicated UTIs, including eradication of resistant Serratia strains.
Impact:
- CMX exhibits favorable pharmacokinetic properties and significant clinical efficacy for UTIs.
- The antibiotic proved effective against pathogens resistant to conventional cephalosporins.
- No significant adverse effects were reported, indicating a good safety profile for CMX in UTI treatment.
Related Concept Videos
Hypertension III: Clinical Manifestations and Diagnostic Studies
Urologic Endoscopic Procedure: Cystoscopic Examination
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
Aneurysm II: Clinical Manifestations and Diagnostic Studies
Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.

